Evidence map›Paper›PMID 39762738›Full record

ArticleBMC bioinformatics2025

SequenceCraft: machine learning-based resource for exploratory analysis of RNA-cleaving deoxyribozymes.

M Eremeyeva, Y Din, N Shirokii, N Serov

Abstract read
In one paragraph

Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M EremeyevaInternational Institute "Solution Chemistry of Advanced Materials and Technologies", ITMO University, Saint-Petersburg, Russian Federation, 191002.
Y DinInternational Institute "Solution Chemistry of Advanced Materials and Technologies", ITMO University, Saint-Petersburg, Russian Federation, 191002.
N ShirokiiInternational Institute "Solution Chemistry of Advanced Materials and Technologies", ITMO University, Saint-Petersburg, Russian Federation, 191002.
N SerovInternational Institute "Solution Chemistry of Advanced Materials and Technologies", ITMO University, Saint-Petersburg, Russian Federation, 191002. serov@scamt-itmo.ru.

Funding

Russian Science Foundation 24-24-00546
6 · The paper itself

Abstract

backgroundDeoxyribozymes or DNAzymes represent artificial short DNA sequences bearing many catalytic properties. In particular, DNAzymes able to cleave RNA sequences have a huge potential in gene therapy and sequence-specific analytic detection of disease markers. This activity is provided by catalytic cores able to perform site-specific hydrolysis of the phosphodiester bond of an RNA substrate. However, the vast majority of existing DNAzyme catalytic cores have low efficacy in in vivo experiments, whereas SELEX based on in vitro screening offers long and expensive selection cycle with the average success rate of ~ 30%, moreover not allowing the direct selection of chemically modified DNAzymes, which were previously shown to demonstrate higher activity in vivo. Therefore, there is a huge need in in silico approach for exploratory analysis of RNA-cleaving DNAzyme cores to drastically ease the discovery of novel catalytic cores with superior activities.

resultsIn this work, we develop a machine learning based open-source platform SequenceCraft allowing experimental scientists to perform DNAzyme exploratory analysis via quantitative observed rate constant (k

conclusionsThis work represents a significant advancement in DNAzyme research, providing a tool for more efficient discovery of RNA-cleaving DNAzymes. The SequenceCraft platform offers an in silico alternative to traditional experimental approaches, potentially accelerating the development of DNAzymes.

Indexed as

DNA, CatalyticMachine LearningComputational BiologyRNADNA, CatalyticRNAArtificial intelligenceCatalytic activityDeoxyribozymesMachine learningWeb resource

Identifiers

PMID39762738
PMCPMC11706003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.